Asker Healthcare Group AB (CHIX:ASKERS) Research & Development: kr0 Mil (TTM As of Mar. 2026)


CHIX:ASKERS Asker Healthcare Group AB CHIX:ASKERS
20 GF Score
Price kr77.50
! 3 Warning Signs
View Full Analysis

What is Asker Healthcare Group AB Research & Development?

Asker Healthcare Group AB CHIX:ASKERS 20 Research & Development is kr0 Mil as of Mar. 2026. GuruFocus rates CHIX:ASKERS with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Asker Healthcare Group AB's Research & Development for the three months ended in Mar. 2026 was kr0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0 Mil.

Asker Healthcare Group AB  (CHIX:ASKERs) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Asker Healthcare Group AB Research & Development Related Terms

Asker Healthcare Group AB Research & Development Historical Data

* Premium members only.

The historical data trend for Asker Healthcare Group AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asker Healthcare Group AB Research & Development Chart

Asker Healthcare Group AB Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00 0.00

Asker Healthcare Group AB Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:ASKERS
20GF Score
Asker Healthcare Group AB CHIX:ASKERS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asker Healthcare Group AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0 Mil mean?
Asker Healthcare Group AB (CHIX:ASKERS) has a Research & Development of kr0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Asker Healthcare Group AB and its competitors.
Is Asker Healthcare Group AB's Research & Development too high?
Asker Healthcare Group AB's current Research & Development is kr0 Mil. Overall, Asker Healthcare Group AB has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Asker Healthcare Group AB's Research & Development compare to MCK and CAH?
Asker Healthcare Group AB's Research & Development of kr0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Asker Healthcare Group AB and its competitors. Asker Healthcare Group AB's current Research & Development is kr0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asker Healthcare Group AB stock overvalued right now?
Asker Healthcare Group AB (CHIX:ASKERS) has a current Research & Development of kr0 Mil. The current Research & Development is kr0 Mil. Asker Healthcare Group AB's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Asker Healthcare Group AB (CHIX:ASKERS), the current Research & Development is kr0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Asker Healthcare Group AB Business Description

Other Exchanges ASKER:SwedenI88:Germany
Address Svardvagen 3A, Danderyd, SWE, 182 33
Asker Healthcare Group AB is a provider of medical products and solutions that drive progress in the European healthcare sector. The company is engaged in building and acquiring companies to support the healthcare system to improve patient outcomes, reduce the total cost of care, and ensure a fair and sustainable value chain. The company also offers a range of value-added solutions to support its suppliers and customers in, for example, market access, efficiency, and sustainability. Company has adapted a twin engine growth strategy that combines organic and acquired growth. Geographically, the company evaluates the operations in three business areas: North, West and Central.
20GF Score

Get the complete analysis for CHIX:ASKERS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr77.50
Price